Bridgewest Group, a company involved in developing innovative companies in life sciences, software, and deep tech, launched a new contract development and manufacturing organization (CDMO) focused on sterile injectable drug products. Located in Western Australia, the CDMO will operate under the name NovaCina.

NovaCina will manufacture sterile injectable drug products for all phases, from development to full scale commercial production. It has over nine production lines across oncology/high potency, blow-fill-seal and multi format vial streams, all supported with more than 400 experienced team members. The company plans to expand its service offerings and broaden its expertise with state-of-the-art equipment and analytics.

Brett Alderson has been named president of NovaCina. He joins the company after 25-plus years at Pfizer (Perth) Pty. Ltd. During the past five years, he was site leader, overseeing the production of over 300 oncology products plus numerous additional sterile injectable medicines for local and global markets.

“I am thrilled to be leading a wonderful group with extensive scientific knowledge, as we journey into our next life as NovaCina,” said Alderson. “Our team is quite exceptional in the industry. The average tenure surpasses 15 years. As such, we have a longstanding history together of delivering premium quality products with agility and professionalism. There is a personal dedication inherent in all of us to consistently rise above expectations. I am honored to take the helm at NovaCina and champion the vibrant pharma community in Perth.”

Under an MSA, NovaCina will continue to manufacture oncology drugs and sterile injectable hospital essentials for Pfizer, while it works to extend its customer base and offerings globally.

Bridgewest Perth Pharma Pty. Ltd, a subsidiary of Bridgewest Group, will oversee and support the continued growth of NovaCina, as well as future investments that broaden and vertically integrate world-class services and products in the life sciences sector. Alderson will also serve as chief operating officer of Bridgewest Perth Pharma.

Masood Tayebi, co-founder and CEO of Bridgewest Group, said, “NovaCina represents one of several strategic acquisitions supporting our global mission to bring life-saving therapeutics to patients in need. Across our portfolio, we’ve assembled an exceptional team, who are innovating in several areas. BioDuro-Sundia is now the third largest global contract research and development manufacturing organization (CRDMO).”